Results 161 to 170 of about 82,568 (267)

Relative Preference of Cannabis, Alcohol, and Nicotine Products Among U.S. Adolescents and Young Adults Who Are Using or Susceptible to Cannabis Use: Insights from a Best-Worst Scaling Study. [PDF]

Subst Use Misuse
Xu L, Zhang S, Elsaid M, Shang C.
europepmc   +1 more source

Prevalence and risk perceptions of nicotine pouch use: A systematic review of population‐based studies

Addiction, EarlyView.
Abstract Background and Aims Oral nicotine pouches (NPs) are a new class of non‐combustible nicotine products that have gained rapid popularity. Despite rising sales and marketing, evidence of their prevalence and risk perceptions remains limited. This systematic review aimed to synthesize the available global evidence on the prevalence and patterns of
Salma Mahmoodianfard, Spencer Shahen, Javad Heshmati, Emma Bates, Evyanne Quirouette, Terefe Gelibo, Sarah Visintini, Hassan Mir   +7 more
wiley   +1 more source

Beyond abstinence: Redefining success in cannabis use disorder treatment

Addiction, EarlyView.
Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin, Frances R. Levin, John Mariani, Christina A. Brezing   +3 more
wiley   +1 more source

Might cannabis Legalization Have Affected Public Health-Relevant Alcohol- and Tobacco-use Outcomes in Canada? [PDF]

Nordisk Alkohol Nark
Fischer B, Hall W, Jutras-Aswad D, Le Foll B.   +3 more
europepmc   +1 more source

Alcohol consumption and cognitive function: A systematic review and dose–response meta‐analysis of 20 cohort studies

Addiction, EarlyView.
Abstract Background and aims Amid ongoing debate on whether low‐to‐moderate alcohol consumption reduces cardiovascular risk, studies examining the association between alcohol consumption and cognitive function have reported inconsistent results. To quantitatively assess this association, we conducted a dose–response meta‐analysis of cohort studies ...
Sooyeun Choi, Youjin Je
wiley   +1 more source

Cannabis use disorder in patients prescribed medical cannabis—Should we consider prescription cannabis use disorder as a new diagnostic condition?

Addiction, EarlyView.
Abstract Background and Aims The introduction of prescribed medical cannabis in many parts of the world raises issues regarding how we conceptualise Cannabis Use Disorders (CUD). The Diagnostic Statistical Manual Version 5 (DSM5) provides a framework for ‘Prescription Cannabis Use Disorder’ (Pr‐CUD) when a person is using medical cannabis only‐as ...
Nicholas Lintzeris, Llewellyn Mills
wiley   +1 more source

Protocol for the REVELIO test-track pilot study: A randomised, controlled, single-centre trial in healthy recreational cannabis users investigating real-time in-vehicle detection of cannabis-impaired driving. [PDF]

PLoS One
Deuber R, Bechny M, Heck C, Brügger J, Pfäffli M, Jovanova M, Fleisch E, Wortmann F, Weinmann W.   +8 more
europepmc   +1 more source

Prescribed pharmaceutical alternatives initiative coinciding with reductions in unregulated street opioid use among young people who use drugs: An interrupted time series analysis

Addiction, EarlyView.
Abstract Background and aims In British Columbia, Canada, an initiative was implemented in 2020 to reduce overdose mortality by prescribing pharmaceutical opioids (primarily hydromorphone) as a substitute for the toxic unregulated drug supply. This study estimated changes in the level and trend of unregulated opioid use and non‐prescribed hydromorphone
Erica McAdam, Mohammad Karamouzian, Michael John Milloy, Carmen Verdicchio, Eric C. Sayre, Kanna Hayashi, Thomas Kerr, Kora DeBeck   +7 more
wiley   +1 more source

Marketing features of derived intoxicating cannabinoid product brands on Instagram: A content analysis

Addiction, EarlyView.
Abstract Background and aims Use of derived intoxicating cannabinoid products (DICPs) has grown in the United States (US), as have associated poisonings, emergency department visits and psychotic episodes. Brand marketing on social media, a largely underregulated marketing channel, may be contributing to this growth.
Kathryn La Capria, Siyan Meng, Alisa A. Padon, Kayla K. Tillett, Scott I. Donaldson, Jon‐Patrick Allem, Matthew E. Rossheim, Cassidy LoParco, Carla J. Berg, Kristina M. Jackson, Julia Chen‐Sankey   +10 more
wiley   +1 more source

Clinical observations during adjunctive Cannabis treatment and subsequent oclacitinib dose reduction in dogs with atopic dermatitis. [PDF]

Front Allergy
Mariga C, da Silva FC, Schiefler OHM, Amazonas E, Mateus ALSS, Schmidt C, Filho STLP.   +6 more
europepmc   +1 more source